World leader in suppositories & pessaries; exports 150+ pharma brands to 60+ countries, mainly Africa.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 10 | 10 | 10 | 10 | 11 | 11 | 11 |
| Reserves | 725 | 798 | 808 | 873 | 957 | 1.0k | 1.1k | 1.2k |
| Borrowings | 126 | 122 | 109 | 102 | 100 | 88 | 52 | 22 |
| Other Liabilities | 168 | 147 | 181 | 171 | 145 | 163 | 215 | 278 |
| Total Liabilities | 1.0k | 1.1k | 1.1k | 1.2k | 1.2k | 1.3k | 1.4k | 1.5k |
| AssetsFixed Assets | 242 | 234 | 281 | 379 | 370 | 406 | 392 | 459 |
| CWIP | 0 | 2 | 22 | 3 | 8 | 21 | 39 | 6 |
| Investments | 0 | 0 | 2 | 8 | 4 | 4 | 10 | 5 |
| Other Assets | 788 | 840 | 803 | 768 | 830 | 871 | 959 | 1.0k |
| Total Assets | 1.0k | 1.1k | 1.1k | 1.2k | 1.2k | 1.3k | 1.4k | 1.5k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 40 | 47 | 64 | 135 | 34 | 103 | 106 | 139 |
| Cash from Investing | -79 | -40 | -45 | -103 | -6 | -83 | -75 | -38 |
| Cash from Financing | 17 | -6 | -21 | -24 | -25 | -21 | -30 | -89 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 2 | -12 | 55 | 63 | -59 | 75 | 33 | 84 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (15.6×) and current (50.8×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 11.9% growth and a 16× exit, ₹486 only delivers your return if you pay ₹117. The price is currently baking in 45% growth.
EPS grows 11.9%/yr for 5 years, then fades to 6% over 2, exits at 16×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 11.9% | 10.72 |
| FY28 | 11.9% | 12.00 |
| FY29 | 11.9% | 13.42 |
| FY30 | 11.9% | 15.02 |
| FY31 | 11.9% | 16.81 |
| FY32 | 8.9% ·fade | 18.31 |
| FY33 | 6.0% ·fade | 19.41 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.